5-Amino-1MQ: NNMT Inhibition Remains a Preclinical Research Question

Reviewed for accuracy by the Gorilla Research Insights research team · 2026-07-04

CELLULAR METABOLISM 5-Amino-1MQ: NNMT Inhibition Remains a Preclinical Research Question 5-Amino-1MQ gives researchers a small-molecule way to probe nicotinamide N-methyltransferase. The published outcome evidence is preclinical and does not establish human efficacy or safety.

The Target: NNMT

Nicotinamide N-methyltransferase, or NNMT, catalyzes transfer of a methyl group from S-adenosylmethionine to nicotinamide. Because that reaction intersects nicotinamide handling and methyl-donor metabolism, NNMT has become an experimental target in metabolic biology. 5-Amino-1MQ is a membrane-permeable NNMT inhibitor developed to interrogate that target ^[1]. A plausible target is not the same thing as a validated medicine. Mechanistic language should describe what was measured, in which model, and with what limitations.

What the Foundational Study Found

The 2017 primary study reported biochemical characterization of NNMT inhibitors and experiments in diet-induced-obese mice. In that mouse model, 5-amino-1MQ was associated with lower body-weight gain and adiposity-related measures than control conditions during the short experimental period ^[1]. A later mouse study evaluated 5A1MQ across body composition, glucose-related variables, liver pathology, pharmacokinetics, and tissue distribution. It reported dose-related effects in that diet-induced-obesity model ^[2]. These experiments strengthen the case that NNMT inhibition has biological activity in mice. They do not establish efficacy, safety, an appropriate exposure, or long-term outcomes in humans.

Why Translation Is the Real Frontier

Animal models are built to isolate mechanisms; people bring genetic diversity, coexisting conditions, concurrent medications, and longer time horizons. A result in diet-induced-obese mice can generate a human research hypothesis, but it cannot support promises about human fat loss, glucose control, energy, or safety. The most important unanswered questions include target selectivity in human tissues, exposure-response relationships, off-target activity, toxicology, and whether modulating NNMT produces a favorable clinical effect at all. Until controlled human evidence answers those questions, “promising preclinical inhibitor” is the accurate category.

FAQ

Has 5-Amino-1MQ been proven to cause weight loss in people? No human randomized outcome trial is cited here. The outcome studies in this evidence set used mice ^[1][2]. Does inhibiting NNMT guarantee a metabolic benefit? No. Target engagement, animal-model effects, and human clinical benefit are separate questions. Does “5 mg” describe molecular weight or a validated regimen? No. It is a catalog fill quantity and must not be interpreted as molecular characterization or human-use guidance.

Primary Sources

• ^[1] Neelakantan H et al. Selective and membrane-permeable small-molecule inhibitors of NNMT reverse high-fat-diet-induced obesity in mice . 2018. • ^[2] Neelakantan H et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction . 2024. This article summarizes preclinical research and is not medical advice. Research materials are not for human or animal use.